BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25419501)

  • 1. Therapies of mucopolysaccharidosis IVA (Morquio A syndrome).
    Tomatsu S; Alméciga-Díaz CJ; Barbosa H; Montaño AM; Barrera LA; Shimada T; Yasuda E; Mackenzie WG; Mason RW; Suzuki Y; Orii KE; Orii T
    Expert Opin Orphan Drugs; 2013 Oct; 1(10):805-818. PubMed ID: 25419501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucopolysaccharidosis IVA and glycosaminoglycans.
    Khan S; Alméciga-Díaz CJ; Sawamoto K; Mackenzie WG; Theroux MC; Pizarro C; Mason RW; Orii T; Tomatsu S
    Mol Genet Metab; 2017; 120(1-2):78-95. PubMed ID: 27979613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morquio A syndrome: diagnosis and current and future therapies.
    Tomatsu S; Yasuda E; Patel P; Ruhnke K; Shimada T; Mackenzie WG; Mason R; Thacker MM; Theroux M; Montaño AM; Alméciga-Díaz CJ; Barrera LA; Chinen Y; Sly WS; Rowan D; Suzuki Y; Orii T
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1(0 1):141-51. PubMed ID: 25345096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA.
    Peracha H; Sawamoto K; Averill L; Kecskemethy H; Theroux M; Thacker M; Nagao K; Pizarro C; Mackenzie W; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Fukao T; Tomatsu S
    Mol Genet Metab; 2018 Sep; 125(1-2):18-37. PubMed ID: 29779902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone Growth Induction in Mucopolysaccharidosis IVA Mouse.
    Rintz E; Herreño-Pachón AM; Celik B; Nidhi F; Khan S; Benincore-Flórez E; Tomatsu S
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management.
    Sawamoto K; Álvarez González JV; Piechnik M; Otero FJ; Couce ML; Suzuki Y; Tomatsu S
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome.
    Tomatsu S; Sawamoto K; Alméciga-Díaz CJ; Shimada T; Bober MB; Chinen Y; Yabe H; Montaño AM; Giugliani R; Kubaski F; Yasuda E; Rodríguez-López A; Espejo-Mojica AJ; Sánchez OF; Mason RW; Barrera LA; Mackenzie WG; Orii T
    Drug Des Devel Ther; 2015; 9():1937-53. PubMed ID: 25897204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment.
    Tomatsu S; Montaño AM; Oikawa H; Smith M; Barrera L; Chinen Y; Thacker MM; Mackenzie WG; Suzuki Y; Orii T
    Curr Pharm Biotechnol; 2011 Jun; 12(6):931-45. PubMed ID: 21506915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice.
    Dvorak-Ewell M; Wendt D; Hague C; Christianson T; Koppaka V; Crippen D; Kakkis E; Vellard M
    PLoS One; 2010 Aug; 5(8):e12194. PubMed ID: 20808938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels.
    Dũng VC; Tomatsu S; Montaño AM; Gottesman G; Bober MB; Mackenzie W; Maeda M; Mitchell GA; Suzuki Y; Orii T
    Mol Genet Metab; 2013; 110(1-2):129-38. PubMed ID: 23876334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA.
    Hendriksz CJ; Harmatz P; Beck M; Jones S; Wood T; Lachman R; Gravance CG; Orii T; Tomatsu S
    Mol Genet Metab; 2013; 110(1-2):54-64. PubMed ID: 23665161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Substrate Degradation Enzyme Therapy for Mucopolysaccharidosis IVA Murine Model.
    Sawamoto K; Tomatsu S
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mucopolysaccharidosis IVA (Morquio A syndrome): clinical, biological and therapeutic aspects].
    Bouzidi H; Khedhiri S; Laradi S; Ferchichi S; Daudon M; Miled A
    Ann Biol Clin (Paris); 2007; 65(1):5-11. PubMed ID: 17264033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative profile exhibited by Mucopolysaccharidosis type IVA patients at diagnosis: Increased keratan urinary levels.
    Donida B; Marchetti DP; Jacques CED; Ribas G; Deon M; Manini P; da Rosa HT; Moura DJ; Saffi J; Giugliani R; Vargas CR
    Mol Genet Metab Rep; 2017 Jun; 11():46-53. PubMed ID: 28487826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Umbilical mesenchymal stem cell-derived extracellular vesicles as enzyme delivery vehicle to treat Morquio A fibroblasts.
    Flanagan M; Pathak I; Gan Q; Winter L; Emnet R; Akel S; Montaño AM
    Stem Cell Res Ther; 2021 May; 12(1):276. PubMed ID: 33957983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Proteomic Analysis in Morquio A Disease.
    Álvarez JV; Bravo SB; Chantada-Vázquez MP; Barbosa-Gouveia S; Colón C; López-Suarez O; Tomatsu S; Otero-Espinar FJ; Couce ML
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The characterisation of pulmonary function in patients with mucopolysaccharidoses IVA: A longitudinal analysis.
    Kenth JJ; Thompson G; Fullwood C; Wilkinson S; Jones S; Bruce IA
    Mol Genet Metab Rep; 2019 Sep; 20():100487. PubMed ID: 31341787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: early treatment rescues bone lesions?
    Tomatsu S; Montaño AM; Oikawa H; Dung VC; Hashimoto A; Oguma T; Gutiérrez ML; Takahashi T; Shimada T; Orii T; Sly WS
    Mol Genet Metab; 2015 Feb; 114(2):195-202. PubMed ID: 24953405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a fluorometric microtiter plate based enzyme assay for MPS IVA (Morquio type A) using dried blood spots.
    Ullal AJ; Millington DS; Bali DS
    Mol Genet Metab Rep; 2014; 1():461-464. PubMed ID: 27896123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A disease.
    Tomatsu S; Orii KO; Vogler C; Nakayama J; Levy B; Grubb JH; Gutierrez MA; Shim S; Yamaguchi S; Nishioka T; Montano AM; Noguchi A; Orii T; Kondo N; Sly WS
    Hum Mol Genet; 2003 Dec; 12(24):3349-58. PubMed ID: 14583446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.